An interventional study of Standard phone call and phone call with MINDSPACE elements in Behavioral Intervention and Nicotine Addiction, sponsored by Medical University of Gdansk. Not yet recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Medical University of Gdansk · Not applicable, Interventional, and Health services research
The goal of this clinical trial is to learn whether different appointment reminder methods can improve attendance at an anti-smoking (smoking cessation) clinic among adult smokers.
The main question it aims to answer is:
"Which reminder method helps participants come to their scheduled smoking cessation clinic appointments most often?" Researchers will compare different appointment reminder methods with standard appointment scheduling to see if they help participants attend their clinic visits more often.
Participants will:
1,027 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.
This study's planned enrollment of 300 is above the median of 90 across 892 interventional studies indexed under Tobacco Use Disorder.
Browse Tobacco Use Disorder studies →Medical University of Gdansk is the lead sponsor of 133 studies on the registry; 46 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a standard, automated text message reminding them of their scheduled appointment. The message will be sent 1 day before the scheduled appointment. The content of the message will be limited to logistical information (date, time, and location) and instructions on how to reschedule or cancel the appointment.
Participants will receive a text message (similar to Arm 1) one day before the appointment and, additionally, a phone call from a trained staff member 1-5 days before the appointment. The conversation will follow a strictly standardized script limited solely to confirming the appointment date, without any motivational or therapeutic elements.
Behavioral: Standard phone call
Participants will receive a short text message (similar to Arm 1) and a phone call 1-5 days before their appointment. The conversation will follow a standardized script incorporating behavioral intervention (nudging) elements based on the MINDSPACE (Messenger, Incentives, Norms, Defaults, Salience, Priming, Affect, Commitments, Ego) framework. Key components of the script include: * Messenger (Sender): Emphasizing that the information comes from the medical team. * Norms (Social Norms): Referring to success statistics for regular visits. * Commitment: Encouraging verbal confirmation of attendance. * Affect (Emotions): Providing short messages reinforcing a sense of support.
Behavioral: phone call with MINDSPACE elements
Participants will receive a phone call from a trained staff member 1-5 days before the appointment. The conversation will follow a strictly standardized script limited solely to confirming the appointment date, without any motivational or therapeutic elements.
Participants will receive a phone call 1-5 days before their appointment. The conversation will follow a standardized script incorporating behavioral intervention (nudging) elements based on the MINDSPACE framework. Key components of the script include: * Messenger (Sender): Emphasizing that the information comes from the medical team. * Norms (Social Norms): Referring to success statistics for regular visits. * Commitment: Encouraging verbal confirmation of attendance. * Affect (Emotions): Providing short messages reinforcing a sense of support.
Also known as: MINDSPACE
Patient attendance at scheduled follow-up visit
Primary Outcome: The primary outcome measure is a binary assessment of patient attendance (Present/Absent) at the scheduled second visit, which takes place 2-8 weeks after the initial visit, as determined by the physician's individual assessment. Attendance will be verified on the day of the scheduled visit based on objective data recorded in the "CliniNET" hospital system.
Time frame: At the second scheduled visit at the Nicotine Cessation Clinic (2-8 weeks after baseline).
Impact of sociodemographic and clinical factors on patient attendance
Secondary Outcomes: Secondary analyses will include an assessment of the impact of sociodemographic and clinical factors based on tests routinely performed as part of a medical visit (age, sex, level of dependence according to the Fagerström Test for Nicotine Dependence (FTND)).
Time frame: at baseline and 2 to 8 weeks after enrollment
Plan to share: No — Individual participant data (IPD) will not be shared with other researchers. Due to privacy and confidentiality concerns, as well as applicable data protection laws, including the General Data Protection Regulation (GDPR), de-identified IPD from individual participants will not be made available.
Start is estimated for Aug 2026; primary completion for Apr 2027, 8 months later.
Of 255 non-industry interventional studies with no phase under Tobacco Use Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's planned 8 months is below that.
Counting every sponsor, half of 265 studies reached it within 32 months; a quarter within 17 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Gdansk →